

# Joachim Yahalom

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/7975124/publications.pdf](https://exaly.com/author-pdf/7975124/publications.pdf)

Version: 2025-02-01

121

PR articles

7,589

PR citations

39430

44

PR h-index

39868

84

g-index

146

documents

10082

doc citations

33350

50

h-index

8656

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020. <i>Neuro-Oncology</i> , 2024, 26, 2061-2073.	1.1	7
2	Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2024, 30, 5083-5093.	6.9	13
3	Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. <i>Leukemia and Lymphoma</i> , 2023, 64, 2195-2201.	1.5	4
4	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, .	7.9	5
5	Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000-2015). <i>Radiotherapy and Oncology</i> , 2022, 173, 179-187.	2.0	13
6	Trends in Use of and Medicare Spending on Short-Course Radiotherapy for Lymphomas From 2015 to 2019. <i>JAMA Health Forum</i> , 2022, 3, e221815.	3.8	4
7	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	4.7	61
8	Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapy. <i>Hematological Oncology</i> , 2021, 39, 304-312.	2.2	5
9	Involved-site radiotherapy for <i>Helicobacter pylori</i> -independent gastric MALT lymphoma: 26 years of experience with 178 patients. <i>Blood Advances</i> , 2021, 5, 1830-1836.	5.1	27
10	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1064-1081.	1.6	51
11	A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. <i>British Journal of Radiology</i> , 2021, 94, .	2.5	1
12	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021, 5, 4185-4197.	5.1	36
13	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	21.6	169
14	The presence of a bulky mediastinal mass of 7%cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT. <i>Leukemia and Lymphoma</i> , 2021, 62, 1313-1324.	1.5	6
15	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. <i>Journal of Cancer Education</i> , 2021, 38, 201-205.	1.1	5
16	Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 279-281.	1.6	5
17	Deauville Dubiosity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 16.	1.6	0
18	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.1	106

#	ARTICLE	IF	PR CITATIONS
19	Excellent Outcomes with Surgery or Radiotherapy in the Management of Castleman Disease Including a Case of Oligocentric Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 685-689.	1.0	18
20	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3382-3390.	5.1	13
21	ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 977-978.	1.6	1
22	Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. <i>Leukemia and Lymphoma</i> , 2020, 61, 3331-3341.	1.5	29
23	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. <i>Blood Advances</i> , 2020, 4, 2064-2072.	5.1	7
24	Diagnostic and Therapeutic Considerations for Extramedullary Leukemia. <i>Current Oncology Reports</i> , 2020, 22, .	4.4	30
25	Radiotherapy for Non-Hodgkin Lymphomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 217-230.	1.8	23
26	Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1500-1503.	1.5	3
27	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 909-933.	1.6	125
28	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. <i>Leukemia</i> , 2020, 35, 130-142.	10.4	98
29	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	4.2	5
30	Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. <i>Journal of Neuro-Oncology</i> , 2019, 144, 553-562.	2.6	60
31	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 501-512.	1.6	43
32	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 522-529.	1.6	18
33	Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. <i>Cancer Medicine</i> , 2019, 8, 58-66.	2.7	50
34	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. <i>Blood</i> , 2019, 133, 237-245.	4.2	117
35	Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 670-678.	1.6	23
36	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1100-1118.	1.6	60

#	ARTICLE	IF	PR CITATIONS
37	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	1.6	92
38	Low-Dose Radiation Conditioning Enables CART T Cells to Mitigate Antigen Escape. <i>Molecular Therapy</i> , 2018, 26, 2542-2552.	10.4	246
39	Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 508-514.	1.6	7
40	Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 314-319.	1.6	45
41	Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. <i>Blood Advances</i> , 2018, 2, 649-655.	5.1	26
42	Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 521-529.	1.6	191
43	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 794-808.	1.6	181
44	Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e279-e281.	1.0	8
45	Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 53-58.	1.6	49
46	Challenges and opportunities in primary CNS lymphoma: A systematic review. <i>Radiotherapy and Oncology</i> , 2017, 122, 352-361.	2.0	44
47	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1066-1076.	1.6	19
48	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage—Case Report. <i>Frontiers in Oncology</i> , 2017, 7, .	2.7	11
49	Curative radiation for orbital MZL: how much?. <i>Blood</i> , 2017, 129, 270-271.	4.2	0
50	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	12.9	120
51	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. <i>Haematologica</i> , 2016, 101, 1237-1243.	4.1	54
52	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	4.2	66
53	Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 175, 440-447.	2.4	30
54	Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 52-59.	2.0	21

#	ARTICLE	IF	PR CITATIONS
55	Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS ONE, 2016, 11, e0155711.	2.4	20
56	Disparities in survival by insurance status in patients with Hodgkin lymphoma. Cancer, 2015, 121, 3515-3524.	4.1	53
57	Innovative Approaches to Radiation Treatment for Mycosis Fungoides in the Setting of Collagen Vascular Disease. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.4	1
58	The role of radiation therapy in the management of primary central nervous system lymphoma. Leukemia and Lymphoma, 2015, 56, 1197-1204.	1.5	27
59	Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 92, 76-83.	1.6	28
60	Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival. International Journal of Radiation Oncology Biology Physics, 2015, 93, 684-693.	1.6	37
61	The concept and evolution of involved site radiation therapy for lymphoma. International Journal of Clinical Oncology, 2015, 20, 849-854.	2.4	31
62	Long-Term Outcomes and Patterns of Relapse of Early-Stage Extranodal Marginal Zone Lymphoma Treated With Radiation Therapy With Curative Intent. International Journal of Radiation Oncology Biology Physics, 2015, 92, 130-137.	1.6	70
63	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	1.6	366
64	Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer, 2015, 121, 1985-1992.	4.1	27
65	Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leukemia and Lymphoma, 2014, 55, 795-801.	1.5	40
66	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Health Physics, 2014, 106, 229-246.	0.9	29
67	Radiotherapy of Follicular Lymphoma: Updated Role and New Rules. Current Treatment Options in Oncology, 2014, 15, 262-268.	4.2	32
68	Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but same (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy. Current Hematologic Malignancy Reports, 2014, 9, 212-216.	2.8	6
69	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma – Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2014, 89, 49-58.	1.6	289
70	A Prospective Study of 18FDG-PET With CT Coregistration for Radiation Treatment Planning of Lymphomas and Other Hematologic Malignancies. International Journal of Radiation Oncology Biology Physics, 2014, 89, 376-383.	1.6	19
71	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROC). International Journal of Radiation Oncology Biology Physics, 2014, 89, 854-862.	1.6	538
72	Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1282-1303.	12.9	160

#	ARTICLE	IF	PR CITATIONS
73	Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1208-1211.	1.5	9
74	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2012, 104, 357-370.	4.7	202
75	Normalization of pre-ASCT, FDG-PET imaging with second-line, non-“cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 1665-1670.	4.2	278
76	Radiation Therapy for Chloroma (Granulocytic Sarcoma). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1816-1822.	1.6	112
77	Non-Hodgkin’s Lymphomas, Version 3.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1487-1498.	12.9	31
78	Long-Term Cardiac and Pulmonary Complications of Cancer Therapy. <i>Heart Failure Clinics</i> , 2011, 7, 403-411.	2.2	6
79	PET-Computed Tomography for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. <i>PET Clinics</i> , 2011, 6, 165-175.	2.0	6
80	[18F]FDG-Positron Emission Tomography Coregistration With Computed Tomography Scans for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 615-622.	1.6	70
81	How I treat extramedullary acute myeloid leukemia. <i>Blood</i> , 2011, 118, 3785-3793.	4.2	444
82	The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1367-1378.	2.6	6
83	Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2010, 116, 4934-4937.	4.2	237
84	High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. <i>British Journal of Haematology</i> , 2010, 148, 890-897.	2.4	95
85	Does radiotherapy still have a place in Hodgkin lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 117-124.	2.8	5
86	Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 158-163.	2.4	141
87	Role of Radiation Therapy in Hodgkin’s Lymphoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 155-160.	1.8	19
88	Low-Dose and Limited-Volume Radiotherapy Alone for Primary Dural Marginal Zone Lymphoma: Treatment Approach and Review of Published Data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1425-1435.	1.6	32
89	Long-Term Cardiac and Pulmonary Complications of Cancer Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 305-318.	2.3	45
90	Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5240-5247.	21.6	71

#	ARTICLE	IF	PR CITATIONS
91	Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity. <i>Journal of Clinical Oncology</i> , 2008, 26, 1858-1864.	21.6	55
92	Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. <i>Journal of Neuro-Oncology</i> , 2008, 91, 315-321.	2.6	111
93	Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4730-4735.	21.6	384
94	Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. <i>Neurology</i> , 2007, 69, 1178-1182.	1.0	183
95	Chemoradiotherapy for primary CNS lymphoma. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 123-136.	0.1	1
96	Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.. <i>Blood</i> , 2007, 110, 1893-1893.	4.2	0
97	Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 1649-1649.	4.2	0
98	Primary bone lymphoma: Treatment results and prognostic factors with long-term follow-up of 82 patients. <i>Cancer</i> , 2006, 106, 2652-2656.	4.1	216
99	Intensity-modulated radiotherapy for lymphoma involving the mediastinum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 198-206.	1.6	97
100	Radiation treatment planning techniques for lymphoma of the stomach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 745-751.	1.6	57
101	Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). <i>European Journal of Haematology</i> , 2005, 75, 90-97.	1.9	55
102	Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. <i>Archives of Neurology</i> , 2005, 62, .	5.9	256
103	Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2004, 124, 645-652.	2.4	150
104	Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. <i>Blood</i> , 2004, 104, 3483-3489.	4.2	264
105	Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 102, 1989-1996.	4.2	243
106	Changing role and decreasing size: Current trends in radiotherapy for hodgkin's disease. <i>Current Oncology Reports</i> , 2002, 4, 415-423.	4.4	13
107	A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i> , 2001, 97, 616-623.	4.2	414
108	Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. <i>Breast Cancer Research and Treatment</i> , 2001, 70, 27-37.	2.4	14

#	ARTICLE	IF	PR CITATIONS
109	Low-grade MALT lymphoma of the stomach: a review of treatment options. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1093-1103.	1.6	77
110	Treatment for Primary CNS Lymphoma: The Next Step. Journal of Clinical Oncology, 2000, 18, 3144-3150.	21.6	588
111	Overexpression of basic fibroblast growth factor (FGF <sup>2</sup> ) downregulates Bcl <sup>2</sup> and promotes apoptosis in MCF <sup>7</sup> human breast cancer cells. Breast Cancer Research and Treatment, 1999, 56, 151-165.	2.4	46
112	Radiation therapy in the treatment of lymphoma. Current Opinion in Oncology, 1999, 11, 370.	2.2	14
113	Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: Lack of correlation between inhibition of cell growth and MAP kinase activation. , 1998, 177, 411-425.		13
114	T-Cell <sup>Depleted</sup> Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. Blood, 1998, 91, 1083-1090.	4.2	221
115	Do not miss a second (and possibly last) chance to cure Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1997, 39, 595-597.	1.6	6
116	The Case for Adjuvant Radiation Therapy in Advanced Hodgkin's Disease. Cancer Investigation, 1996, 14, 361-370.	1.7	19
117	Management of relapsed and refractory Hodgkin's disease. Seminars in Radiation Oncology, 1996, 6, 210-224.	2.7	11
118	Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer, 1993, 71, 2342-2350.	4.1	87
119	Pulmonary Complications in Lymphoma Patients Treated with High-Dose Therapy and Autologous Bone Marrow Transplantation. The American Review of Respiratory Disease, 1992, 146, 485-491.	3.3	105
120	Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer. Cancer, 1990, 66, 844-847.	4.1	41
121	Treatment Options for Hodgkin's Disease During Pregnancy. Leukemia and Lymphoma, 1990, 2, 151-161.	1.5	11